Asia-Pacific Prophylaxis Of Organ Rejection Market By Cause (Epidemiologic Exposure, Antibacterial Prophylaxis, Prophylaxis Against Other Pathogens And Others.), Treatment(Outpatient Immunosuppressant, Inpatient Immunosuppressant And Others), Route Of Administration (Oral, Intravenous), By Organ (Kidney, Liver, Heart, Lung, Others), Patient Type (Paediatric, Adults), End User (Hospitals, Clinic Home Healthcare And Others), Distribution Channel (Direct Tender, Pharmacy Stores And Others), By Country Asia-Pacific (Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, & Rest Of Asia-Pacific) Industry Trends And Forecast To 2029.
Market Analysis and Insights: Asia-Pacific Prophylaxis of Organ Rejection Market
Asia-Pacific prophylaxis of organ rejection market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2022 to 2029 and is expected to reach USD 943.85 million by 2029 from USD 599.21 million in 2021. The rising prevalence of organ transplantation and increased use of immunosuppressant are likely to be the major drivers which propel the demand of the market in the forecast period.
The term prophylaxis means treatment given or action taken to prevent disease. The prophylaxis of organ rejection, refers to the prevention of organ rejection by use of medicines. The patients who undergo transplantation, must be maintained on an immunosuppression regimen for rejection prophylaxis to help ensure graft survival. The transplant rejection is a process, in which a transplant recipient’s immunity the current rejection prophylaxis implements use of calcineurin inhibitors, mTOR inhibitors, antimetabolite agents, and corticosteroids. The treatment agents improve the short term consequences of the organ transplantation, but certain improvements. The recipient patients, who have undergone solid organ transplantation, should take anti-rejection medicines. This is because the immunity system would destroy the transplanted organ.
The driving factors responsible for the growth of the Asia-Pacific prophylaxis of organ rejection market are the increased prevalence of organ transplantation, rise in surgical procedures, rise in recipient population and product launches. However, the factors that are expected to restrain the market are the rise in the cost of the transplantation procedure, lack of awareness about organ transplantation and the risks included while the patient receives the transplanted organ.
On the other hand, strategic initiatives by market players, rise in research and developments and use of immunosuppressant may act as an opportunity for the growth of the Asia-Pacific prophylaxis of organ rejection market. The need for skilled expertise and the regulatory approval may create challenges for the Asia-Pacific prophylaxis of organ rejection market. There are recent developments related to the Asia-Pacific prophylaxis of organ rejection market.
Asia-Pacific prophylaxis of organ rejection market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia- Pacific Prophylaxis of Organ Rejection Market Scope and Market Size
Asia- Pacific prophylaxis of organ rejection market is segmented on the basis of cause, treatment route of administration, organ, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
The Asia-Pacific prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
- On the basis of cause, the Asia-Pacific prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. In 2022, the epidemiologic exposure segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in China
- On the basis of treatment, the Asia-Pacific prophylaxis of organ rejection market is segmented into outpatient immunosuppressant, inpatient immunosuppressant and others. In 2022, the outpatient immunosuppressant segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market, since it can achieve the sustained and specific immune response against damaged cells and avialability of cyclosporine in the Shanghai.
- On the basis of route of administration, the Asia-Pacific prophylaxis of organ rejection market is segmented into oral and intravenous. In 2022, the oral segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection due to increased availability and intake of oral tablets and capsules.
- On the basis of organ, the Asia-Pacific prophylaxis of organ rejection market is segmented into kidney, liver, heart, lung and others. In 2022, the kidney segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection due to increased incidence of kidney failure and presence of reimbursement policies such as Medicare, for the recipient’s insurance.
- On the basis of patient type, the Asia-Pacific prophylaxis of organ rejection market is segmented into pediatric and adults. In 2022, the adults segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market, due to increased prevalence of chronic diseases and genetic conditions of the adult patients, weak immune system in adults and waiting list of adult recipients more than the waiting list of children and women in New Mexico and the U.S.
- On the basis of end user, the Asia-Pacific prophylaxis of organ rejection market is segmented into hospitals, clinics, home healthcare and others. In 2022, the hospitals segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market due to rise in medical care and collaboration with other hospitals in Asia-Pacific for delivery of the donor organs to the recipient patients are predicted to dominate the market.
- On the basis of distribution channel, the Asia-Pacific prophylaxis of organ rejection market is segmented into direct tenders, pharmacy stores and others. In 2022, the direct tenders segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market due to surge in demand of outpatient immunosuppressant by pharmaceutical companies and guaranteed payment, are predicted to dominate the market.
Asia-Pacific Prophylaxis of Organ Rejection Market Country Level Analysis
Asia- Pacific prophylaxis of organ rejection market is segmented on the basis of cause, treatment route of administration, organ, end user and distribution channel.
The countries covered in the prophylaxis of organ rejection market report are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.
Asia-Pacific is expected to grow with the highest CAGR in the forecasted periods as in the Asia-Pacific’s countries demand for prophylaxis of organ rejection product is increasing very rapidly with the urbanization and laboratory automation. China is expected to dominate in the market in the Asia-Pacific market. China is one of the leading countries to inculcate prophylaxis of organ rejection market, due to rise in patient population, waiting for organ transplantation and rise in surgical procedures.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growth Potential for Prophylaxis of Organ Rejection in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Asia-Pacific Prophylaxis of Organ Rejection Market
Asia Pacific Prophylaxis of organ rejectionMarket also provides you with detailed market analysis for every country growth in particular industry with prophylaxis of organ rejection sales, impact of advancement in the prophylaxis of organ rejection and changes in regulatory scenarios with their support for the prophylaxis of organ rejection market. The data is available for historic period 2020 to 2021.
Competitive Landscape and Asia Pacific Prophylaxis of organ rejection Market Share Analysis
Asia Pacific prophylaxis of organ rejection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prophylaxis of organ rejection market.
The major companies providing the Asia- Pacific prophylaxis of organ rejection are Concord Biotech, Panacea Biotec, WOCKHARDT, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy’s Laboratories, Ltd, Viatris Inc, Strides Pharma Science Limited, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited, Hikma Pharmaceuticals PLC, AbbVie Inc, Apotex Inc, Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., ZHEJIANG HISUN PHARMACEUTICAL Co., LTD., CSL Behring among others.
DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players along with new technological advancements for prophylaxis of organ rejection are bridging the gap for chronic wounds treatment.
For instance,
- In September 2021, Novartis Ag had discontinued the use of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients. The analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant. The clinical trial discontinued would result in late approval of the medicine.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the prophylaxis of organ rejection market which also provides the benefit for organisation to improve their offering for prophylaxis of organ rejection market.
SKU-
SKU-